Overview
Vitestro creates autonomous phlebotomy systems for high-volume outpatient settings. Its Aletta device uses multimodal imaging, robotic needle guidance and AI to locate a suitable vein, insert the needle and collect diagnostic blood samples without human intervention. The system standardizes the blood-drawing process to improve consistency, reduce staffing pressure and enhance patient experience, while pursuing regulatory approval paths (FDA De Novo in the US and European deployments) and expanding manufacturing and commercialization. The company differentiates itself through a CE-marked autonomous robotic phlebotomy platform backed by collaborations with major healthcare partners (Labcorp Venture Fund, Mayo Clinic, Sutter Health) and a focus on scalable, high-throughput blood collection. Its goal is to enable safer, reliable and efficient outpatient phlebotomy at scale.
Work here?Claim your company
Simplify's take
What believers are saying
- March 2026’s $70 million Series B funds manufacturing scale-up and U.S. commercialization.
- Labcorp, Mayo Clinic, and Sutter Health validate U.S. clinical credibility and purchasing pathways.
- Odense University Hospital ordered three devices, showing European demand before U.S. launch.
What critics are saying
- U.S. adoption depends on a multicenter trial; delays push revenue into 2027.
- Hospital phlebotomy unions and risk managers can block autonomous blood draws after adverse events.
- Single-product dependence makes Vitestro existentially fragile if Aletta underperforms clinically or commercially.
What makes Vitestro unique
- Vitestro’s Aletta autonomously draws blood; FDA granted De Novo on 20 August 2026.
- CE-marked Aletta combines multimodal imaging, robotics, and AI for vein detection and insertion.
- Vitestro signed five customers for 13 devices by February 2025, proving workflow demand.
Help us improve and share your feedback! Did you find this helpful?